Schizophrenia Clinical Trial
— PEPSYV@SIOfficial title:
Clinical and Brain Effects of Remote Web-based Adapted Physical Activity (e-APA) in Patients With Psychotic Disorders and Healthy Subjects: A Controlled, Multicenter Study
Verified date | July 2021 |
Source | University Hospital, Caen |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
In this study, an APA program by web (e-APA) will be offered to two groups of participants (21 patients and 21 healthy volunteers (HV)) in remote video (use of the SAPATIC (Santé Activités Physiques Adaptées utilisant les Technologies de l'Information et de la Communication) platform developed by the company V@SI). At the same time, two control groups, a group of 21 patients and a group of 21 HV will undergo an health education program (HE) through the collaborative SAPATIC health platform of V@Si and will constitute the control groups. The content of the APA sessions will be administered by V@Si. This program offers content aimed to improve aerobic capacity and muscular strength while relying on the motivation of the participants
Status | Terminated |
Enrollment | 62 |
Est. completion date | June 22, 2021 |
Est. primary completion date | June 22, 2021 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 60 Years |
Eligibility | Inclusion Criteria: Patients: - Be over 18 years of age and under 60 years of age - with schizophrenia or schizoaffective disorder according to DSM-IV (Diagnostic and Statistical Manual of Mental Disorders, 4th edition) criteria established with a semi-structured interview (Mini International Neuropsychiatric Interview, French version 5.0.0). - The possibility of receiving each of the 2 interventions (APA or HE) - No change in psychotropic drugs (antidepressants, antipsychotics or mood regulators) during the 2 months prior to inclusion for patients. - Collecting the signature of informed consent. - The need to be affiliated to a medical welfare - The agreement of the guardian or trustee in case of a protected major Healthy Volunteers: - between 18 and 60 years old - The possibility of receiving each of the 2 interventions (APA or HE) - Collecting the signature of informed consent. - The need to be affiliated to a medical welfare Exclusion Criteria: Patients with only one of the non-inclusion criteria may not be eligible to participate in the research. These criteria are: - Age under 18 or over 60 years old - Pregnancy - The inclusion of the patient in another biomedical research protocol (during the present study) - Patients with progressive neurological disease - Patients with contraindications to MRI (including electronic or metal implants) - Patients who refused to wear earplugs during the MRI examination - Patients with a physical contraindication to physical activity (moderate to severe heart failure, severe valvular disease, unstable coronary disease, acute pulmonary embolism or untreated deep venous thrombosis, uncontrolled hypertension, pulmonary arterial hypertension, treaty) - Neuromuscular pathologies, severe sensory and / or motor neuropathy - Rheumatic and articular pathologies; Rheumatologic / orthopedic problems or bone lesions at risk of fracture contraindicating physical activity - History of stroke or myocardial infarction less than 6 months old at the selection visit Healthy Volunteers Participants with only one of the non-inclusion criteria may not be eligible to participate in the research. These criteria are: - Age under 18 or over 60 years old - Pregnancy - Inclusion of the participant in another biomedical research protocol (during this study) - Participants with progressive neurological disease - Participants with a contraindication to MRI (including electronic or metal implants) - Participants refused to wear ear plugs during the MRI examination - Participants with life-long schizophrenia or schizoaffective disorder according to the DSM-IV criteria established with a semi-structured interview (Mini International Neuropsychiatric Interview, MINI; French version 5.0.0). - Presence of cardiovascular pathologies contraindicating physical activity (moderate to severe heart failure, severe valvular disease, unstable coronary disease, acute pulmonary embolism or untreated deep venous thrombosis, uncontrolled hypertension, pulmonary arterial hypertension, rhythm disorder untreated) - Neuromuscular pathologies, severe sensory and / or motor neuropathy - Rheumatic and articular diseases, rheumatological / orthopedic problems or fracture risk bone lesions - History of stroke or myocardial infarction less than 6 months old at the selection visit |
Country | Name | City | State |
---|---|---|---|
France | Caen University Hospital | Caen |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Caen | Centre Hospitalier du Rouvray |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | hippocampal volumes | The primary endpoint is the right and left hippocampal volumes | at Day 127 +/- 8 days or after 10 sessions of APA if premature cessation of treatment | |
Secondary | Cerebral variables | changes in the different subregions of the hippocampus (CA1, CA2-3-4, subiculum and dentate gyrus, cortical thickness, N-acetyl aspartate (NAA) and glutamate as well as changes in the white matter through the diffusion markers (fractional anisotropy, radial diffusivity and mean diffusivity in the frontomedial-hippocampal fibers) and cerebral irrigation | at Day 127 +/- 8 days or after 10 sessions of APA if premature cessation of treatment | |
Secondary | Physiological variables | neuromuscular, cardiovascular (heart rate variability) and aerobic (VO2) | at Day 127 +/- 8 days or after 10 sessions of APA if premature cessation of treatment | |
Secondary | Circadian rhythms | temperature, actimetry and wake-sleep cycle | at Day 127 +/- 8 days or after 10 sessions of APA if premature cessation of treatment | |
Secondary | Clinical status | severity of symptoms, quality of life, level of activity and physical abilities | at Day 127 +/- 8 days or after 10 sessions of APA if premature cessation of treatment | |
Secondary | Biological variables | fasting glucose, triglycerides, total cholesterol, HDLc, LDLc | at Day 127 +/- 8 days or after 10 sessions of APA if premature cessation of treatment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05039489 -
A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT05111548 -
Brain Stimulation and Cognitive Training - Efficacy
|
N/A | |
Completed |
NCT05321602 -
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
|
Phase 1 | |
Completed |
NCT04503954 -
Efficacy of Chronic Disease Self-management Program in People With Schizophrenia
|
N/A | |
Completed |
NCT02831231 -
Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium
|
Phase 1 | |
Completed |
NCT05517460 -
The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center
|
N/A | |
Completed |
NCT03652974 -
Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy
|
Phase 4 | |
Recruiting |
NCT04012684 -
rTMS on Mismatch Negativity of Schizophrenia
|
N/A | |
Recruiting |
NCT04481217 -
Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT00212784 -
Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)
|
Phase 3 | |
Completed |
NCT04092686 -
A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
|
Phase 3 | |
Completed |
NCT01914393 -
Pediatric Open-Label Extension Study
|
Phase 3 | |
Recruiting |
NCT03790345 -
Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics
|
Phase 2/Phase 3 | |
Recruiting |
NCT05956327 -
Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training
|
N/A | |
Terminated |
NCT03209778 -
Involuntary Memories Investigation in Schizophrenia
|
N/A | |
Completed |
NCT02905604 -
Magnetic Stimulation of the Brain in Schizophrenia or Depression
|
N/A | |
Recruiting |
NCT05542212 -
Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia
|
N/A | |
Completed |
NCT04411979 -
Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia
|
N/A | |
Terminated |
NCT03220438 -
TMS Enhancement of Visual Plasticity in Schizophrenia
|
N/A | |
Completed |
NCT02304432 -
Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine
|
Early Phase 1 |